<DOC>
	<DOCNO>NCT01122875</DOCNO>
	<brief_summary>This multicenter , open-label , dose-escalation study MFGR1877S patient relapse refractory ( 4 ; 14 ) -positive multiple myeloma .</brief_summary>
	<brief_title>A Study Safety Pharmacokinetics MFGR1877S Patients With Relapsed Refractory ( 4 ; 14 ) -Positive Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<criteria>ECOG performance status 0 , 1 , 2 Life expectancy least 12 week Histologic documentation previously treat ( 4 ; 14 ) positive multiple myeloma effective standard therapy exist Prior use monoclonal antibody study treatment Treatment radiotherapy , thalidomide , lenalidomide , bortezomib , chemotherapeutic agent , treatment investigational anticancer agent within 4 week study treatment Completion autologous stem cell transplant within 6 month prior study treatment Prior allogeneic stem cell transplant History severe allergic anaphylactic reaction monoclonal antibody therapy Evidence significant , uncontrolled concomitant disease , include significant cardiovascular disease pulmonary disease Known active bacterial , viral , fungal , mycobacterial , parasitic , infection screen recent major episode infection require treatment IV antibiotic hospitalization prior study treatment Recent major surgery ( prior study treatment ) , diagnosis Presence positive test result Hepatitis B Hepatitis C Known history HIV seropositive status Women pregnant lactate Childbearing potential without agreement use effective form contraception duration study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>